New inhaled drug KIT2014 tested for COPD – early trial begins

NCT ID NCT07668518

Not yet recruiting Disease control Sponsor: Kither Biotech Srl Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests an inhaled drug called KIT2014 in 36 adults with moderate to severe COPD. Participants will receive either the drug or a placebo daily for 7 days. The main goal is to check safety and how the body handles the drug, with a first look at whether it might help breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KIT2014 (inhaled drug)
What this could lead to: If it works, this could point toward a new inhaled treatment to help control COPD symptoms and improve lung function.
What could go wrong: This is an early-phase trial with only 36 people and 7 days of treatment. It is designed mainly to check safety, not to prove effectiveness. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Novatrials

Charlestown, New South Wales, 2291, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.